Skip to content
TrialScanner

NCT03345082

A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD

Phase 2CompletedCKDXFLead

Registry record

Lead sponsor
Opthea Limited
Conditions
Neovascular Age-related Macular Degeneration
Primary completion
May 14, 2019Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT03345082 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT03345082: A Dose Ranging Study of... | TrialScanner